US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(CSE:
QNTM
)
4.510
UNCHANGED
Last Price
Updated: 3:15 PM EDT, Sep 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about QNTM
< Previous
1
2
3
4
5
6
Next >
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in NetworkNewsAudio Editorial on Multiple Sclerosis
June 26, 2026
Via
Investor Brand Network
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
June 26, 2026
From
NetworkNewsWire
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment
June 25, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
June 25, 2026
From
Quantum BioPharma Ltd.
Via
GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
May 28, 2026
Via
Investor Brand Network
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
June 24, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program
June 23, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
June 23, 2026
From
Quantum BioPharma Ltd.
Via
GlobeNewswire
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
From
BioMedWire
Via
GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
June 22, 2026
Via
Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
Via
Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026
From
BioMedWire
Via
GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment
June 08, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets
June 03, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Engages Stocks.news for Investor Relations Services
June 02, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
June 02, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
June 02, 2026
Via
Investor Brand Network
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
June 02, 2026
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study
May 18, 2026
Via
Investor Brand Network
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
May 18, 2026
Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
May 07, 2026
Investigational New Drug (IND) Application Filed to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
April 22, 2026
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
April 02, 2026
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
April 01, 2026
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
March 30, 2026
Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting...
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
March 27, 2026
Financial Statements as of Date of Filing Show Strong Improvements in Cash, Reduction in Accounts Payable, and a Cash Runway Through January 2028
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
March 26, 2026
Highlights advancement of first-in-class neuroprotective candidate targeting demyelination
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
March 23, 2026
unbuzzd Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Completes 180-Day Toxicity Studies for Lucid-MS
December 23, 2025
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
Next >
